Long-term survey of outcome in acute promyelocytic leukemia: A single center experience in 340 patients

Medical Oncology

Volumn 28, Issue SUPPL. 1, 2011, Pages

  Liu, Yue Jun ^a   Wu, De Pei ^a   Liang, Jian Ying ^a   Qiu, Hui Ying ^a   Jin, Zheng Ming ^a   Tang, Xiao Wen ^a   Fu, Cheng Cheng ^a   Ma, Xiao ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

Acute promyelocytic leukemia; Long term survival; Prognostic factors

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CHINESE DRUG; CYTARABINE; DAUNORUBICIN; FIBRINOGEN; FRESH FROZEN PLASMA; HEMOGLOBIN; HUANGDAIPIAN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; RETINOIC ACID; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN HEMORRHAGE; CANCER MORTALITY; CANCER SURVIVAL; CAUSE OF DEATH; CHILD; CYTOGENETICS; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; LONG TERM CARE; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; RISK FACTOR; SCHOOL CHILD; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME; URINARY TRACT HEMORRHAGE;

EID: 84655176706     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9733-7     Document Type: Review

References (25)

1. G Avvisati F Lo Coco F Mandelli 2001 Acute promyelocytic leukemia: clinical and morphologic features and prognostic factors Semin Hematol 38 4 12 (Pubitemid 32107698)
2. MS Tallman CH Nabhan JH Feusner JM Rowe 2002 Acute promyelocytic leukemia: evolving therapeutic strategies Blood 99 759 767 (Pubitemid 34525534)
3. D Grimwade F Lo Coco 2002 Acute promyelocytic leukemia:a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia Leukemia 16 1959 1973 (Pubitemid 35203438)
4. ZY Wang Z Chen 2008 Acute promyelocytic leukemia: from highly fatal to highly curable Blood 111 2505 2515
5. MS Tallman JW Andersen CA Schiffer FR Appelbaum JH Feusner A Ogden 1997 All-trans-retinoic acid in acute promyelocytic leukemia N Engl J Med 337 1021 1028 (Pubitemid 27430519)
6. F Mandelli D Diverio G Avvisati A Luciano T Barbui C Bernasconi 1997 Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-malattie ematologiche maligne dell'adulto and associazione Italiana di ematologia ed oncologia pediatrica cooperative groups Blood 90 1014 1021
7. P Fenaux C Chastang S Chevret M Sanz H Dombret E Archimbaud 1999 A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapyand ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia Blood 94 1192 1200 (Pubitemid 29380399)
8. MA Sanz G Martin C Rayon J Esteve M Gonza′lez J DI′az-Mediavilla 1999 A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RAR alpha-positive acute promyelocytic leukemia Blood 94 3015 3021 (Pubitemid 29512705)
9. E Lengfelder A Reichert C Schoch D Haase T Haferlach H Löffler 2000 Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML cooperative group Leukemia 14 1362 1370 (Pubitemid 30601354)
10. BD Cheson JM Bennett KJ Kopecky T Büchner CL Willman EH Estey 2003 Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia J Clin Oncol 21 4642 4649 (Pubitemid 46594039)
11. J de la Serna P Montesinos E Vellenga C Rayón R Parody A León 2008 Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin Blood 111 3395 3402
12. M Yanada T Matsushita N Asou Y Kishimoto M Tsuzuki Y Maeda 2007 Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia:incidence, risk factors, and influence on outcome Eur J Haematol 78 213 219
13. P Fenaux MC Le Deley S Castaigne E Archimbaud C Chomienne H Link 1993 Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 group Blood 82 3241 3249 (Pubitemid 23356690)
14. E Estey PF Thall S Pierce H Kantarjian M Keating 1997 Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine J Clin Oncol 15 483 490 (Pubitemid 27074214)
15. MA Sanz G Martin M Gonzalez A Leon C Rayon C Rivas 2004 Risk adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group Blood 103 1237 1243 (Pubitemid 38168633)
16. L Adès A Guerci E Raffoux M Sanz P Chevallier S Lapusan 2010 Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL group experience Blood 115 1690 1696
17. MS Tallman JW Andersen CA Schiffer FR Appelbaum JH Feusner WG Woods 2002 All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American intergroup protocol Blood 100 4298 4302 (Pubitemid 36001941)
18. S De Botton S Chevret M Sanz H Dombret X Thomas A Guerci 2000 Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial Br J Haematol 111 801 806 (Pubitemid 32098918)
19. J Cervera P Montesinos JM Hernández-Rivas MJ Calasanz A Aventín MT Ferro 2010 Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy Haematologica 95 3 424 431
20. MA Sanz P Montesinos C Rayón A Holowiecka J de la Serna G Milone 2010 Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome Blood 115 5137 5146
21. C Kelaidi S Chevret S De Botton E Raffoux A Guerci X Thomas 2009 Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 Years: the European APL group experience J Clin Oncol 27 2668 2676
22. D Diverio V Rossi G Avvisati S De Santis A Pistilli F Pane 1998 Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP multicenter "AIDA" trial Blood 92 784 789 (Pubitemid 28355460)
23. F Lo Coco D Diverio PP Pandolfi A Biondi V Rossi G Avvisati 1992 Molecular evaluation of residual disease as predictor of relapse in acute promyelocytic leukaemia Lancet 340 1437 1438
24. RE Gallagher BY Yeap W Bi KJ Livak N Beaubier S Rao 2003 Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129 Blood 101 2521 2528 (Pubitemid 36857607)
25. JG Jurcic SD Nimer DA Scheinberg T DeBlasio RP Warrell Jr WH Miller Jr 2001 Prognostic significance of minimal residual disease detection and PML/RARa isoform type: long-term follow-up in acute promyelocytic leukemia Blood 98 2651 2656